Codex Alimentarius Commission  
40th Session  
Geneva, 17 – 22 July 2017

European Union comments on the  
Proposed draft MRLs for lasalocid sodium, ivermectin and teflubenzuron  
at step 5/8  
(CL 2016/38-RVDF)

European Union Competence  
European Union Vote

Lasalocid sodium

The European Union (EU) would like to reiterate its reservation to the adoption of the proposed draft MRLs for lasalocid sodium at step 5/8.

The EU considers that a risk to consumers cannot be ruled out, as in the absence of a methodology for derivation of a microbiological acute reference dose, there is no health-based guidance value with which to satisfactorily compare the acute exposure.

Ivermectin

1. Proposed Draft MRL for ivermectin for muscle  
The EU can support the proposed draft MRL.

2. Proposed draft MRLs for ivermectin for fat, kidneys and liver  
The EU does not object to the proposed draft MRLs for ivermectin in fat, kidneys and liver.

Teflubenzuron

The EU does not object to the proposed draft MRLs for teflubenzuron.